Literature DB >> 15947872

Hereditary colorectal cancer syndromes.

Lisa L Strate1, Sapna Syngal.   

Abstract

The purpose of this article is to review the genetic colorectal cancer syndromes including Hereditary Nonpolyposis Colorectal Cancer (HNPCC), Family Polyposis (FAP) and the hamartomatous polyposis syndromes. HNPCC is the most common of the hereditary colorectal cancer syndromes, and is the result of defects in the mismatch repair genes. Individuals with HNPCC have an 80 lifetime risk of colorectal cancer, and in females a 30-50% risk of endometrial cancer, as well as predisposition for a number of other malignancies. Early screening and interval surveillance for colorectal and endometrial cancer are recommended. In FAP, mutations in the Adenomatous Polyposis Coli (APC) tumor suppressor gene give rise to hundreds to thousands of colorectal polyps, some of which will inevitably progress to cancer. Early diagnosis and timely prophylactic colectomy prevent this outcome. Chemoprevention with nonsteroidal anti-inflammatory drugs can reduce adenoma number and size in FAP, but the effect is incomplete. In addtion, surveillance for upper gastrointestinal tract malignancies is necessary. Attenuated forms of FAP may be the result of mutations in the APC gene, or in the recently described MYH gene. Mutations in the MYH gene should be considered in individuals with multiple adenomas whose family history does not reflect an autosomal dominant pattern of inheritance. The hamartomatous polyposis syndromes are uncommon but distinctive disorders in which multiple hamartomatous polyps develop at a young age. Our understanding of the genetic basis of these disorders is improving, and a predisposition for gastrointestinal and other malignancies has recently been recognized. This article summarizes the genetics, clinical manifestations and clinical management of each of these syndromes with an emphasis on genetic testing and prevention.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15947872     DOI: 10.1007/s10552-004-3488-4

Source DB:  PubMed          Journal:  Cancer Causes Control        ISSN: 0957-5243            Impact factor:   2.506


  35 in total

1.  Tumor suppression and normal aging in mice with constitutively high p53 activity.

Authors:  Susan M Mendrysa; Kathleen A O'Leary; Matthew K McElwee; Jennifer Michalowski; Robert N Eisenman; Douglas A Powell; Mary Ellen Perry
Journal:  Genes Dev       Date:  2006-01-01       Impact factor: 11.361

Review 2.  Base-excision repair of oxidative DNA damage.

Authors:  Sheila S David; Valerie L O'Shea; Sucharita Kundu
Journal:  Nature       Date:  2007-06-21       Impact factor: 49.962

3.  Genetic testing of children at risk for adult onset conditions: when is testing indicated?

Authors:  N Lwiwski; C R Greenberg; A A Mhanni
Journal:  J Genet Couns       Date:  2008-07-08       Impact factor: 2.537

4.  PKG inhibits TCF signaling in colon cancer cells by blocking beta-catenin expression and activating FOXO4.

Authors:  I-K Kwon; R Wang; M Thangaraju; H Shuang; K Liu; R Dashwood; N Dulin; V Ganapathy; D D Browning
Journal:  Oncogene       Date:  2010-03-29       Impact factor: 9.867

5.  A germline missense mutation in exon 3 of the MSH2 gene in a Lynch syndrome family: correlation with phenotype and localization assay.

Authors:  Francesca Bianchi; Elena Maccaroni; Laura Belvederesi; Cristiana Brugiati; Riccardo Giampieri; Federica Bini; Raffaella Bracci; Silvia Pagliaretta; Michela Del Prete; Francesco Piva; Alessandra Mandolesi; Marina Scarpelli; Rossana Berardi
Journal:  Fam Cancer       Date:  2018-04       Impact factor: 2.375

6.  Knowledge, attitudes, and clinical experience of physicians regarding preimplantation genetic diagnosis for hereditary cancer predisposition syndromes.

Authors:  Amanda C Brandt; Matthew L Tschirgi; Kaylene J Ready; Charlotte Sun; Sandra Darilek; Jacqueline Hecht; Banu K Arun; Karen H Lu
Journal:  Fam Cancer       Date:  2010-09       Impact factor: 2.375

Review 7.  Current and future molecular diagnostics in colorectal cancer and colorectal adenoma.

Authors:  Andy Hin-Fung Tsang; Ka-Ho Cheng; Apple Siu-Ping Wong; Simon Siu-Man Ng; Brigette Buig-Yue Ma; Charles Ming-Lok Chan; Nancy Bo-Yin Tsui; Lawrence Wing-Chi Chan; Benjamin Yat-Ming Yung; Sze-Chuen Cesar Wong
Journal:  World J Gastroenterol       Date:  2014-04-14       Impact factor: 5.742

8.  Toll-like receptor 5 engagement modulates tumor development and growth in a mouse xenograft model of human colon cancer.

Authors:  Sang Hoon Rhee; Eunok Im; Charalabos Pothoulakis
Journal:  Gastroenterology       Date:  2008-04-23       Impact factor: 22.682

9.  The genomics of colorectal cancer: state of the art.

Authors:  Andrew D Beggs; Shirley V Hodgson
Journal:  Curr Genomics       Date:  2008-03       Impact factor: 2.236

10.  Performance of clinical guidelines compared with molecular tumour screening methods in identifying possible Lynch syndrome among colorectal cancer patients: a Norwegian population-based study.

Authors:  G Tranø; W Sjursen; H H Wasmuth; E Hofsli; L J Vatten
Journal:  Br J Cancer       Date:  2010-01-05       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.